يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Sebastian, M"', وقت الاستعلام: 1.31s تنقيح النتائج
  1. 1
    دورية أكاديمية
    A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer.

    المؤلفون: Schmittel, A.1, Sebastian, M.2, Fischer von Weikersthal, L.3, Martus, P.4, Gauler, T. C.5, Kaufmann, C.1, Hortig, P.6, Fischer, J. R.7, Link, H.8, Binder, D.9, Fischer, B.2, Caca, K.10, Eberhardt, W. E. E.5, Keilholz, U.1

    المصدر: Annals of Oncology. Aug2011, Vol. 22 Issue 8, p1798-1804. 7p.

    مصطلحات موضوعية: *SMALL cell lung cancer, *ETOPOSIDE, *DISEASE progression, *HEMATOLOGY, *DRUG toxicity, *RANDOMIZED controlled trials, *MEDICAL statistics

    النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    66P Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice.

    المؤلفون: Sebastian, M1 (AUTHOR), Barlesi, F2 (AUTHOR), Califano, R3 (AUTHOR), Mansfield, A S4 (AUTHOR), Blackhall, F H5 (AUTHOR), Flahavan, E M5 (AUTHOR), Davies, J5 (AUTHOR), Arnold, P6 (AUTHOR), Morris, S6 (AUTHOR), Reck, M7 (AUTHOR)

    المصدر: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p. 1 Chart.

    مصطلحات موضوعية: *SMALL cell lung cancer

    النص الكامل

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†.

    المؤلفون: Reck, M.1, Bondarenko, I.2, Luft, A.3, Serwatowski, P.4, Barlesi, F.5, Chacko, R.6, Sebastian, M.7, Lu, H.8, Cuillerot, J. -M.8, Lynch, T. J.9

    المصدر: Annals of Oncology. Jan2013, Vol. 24 Issue 1, p75-83. 9p.

    مصطلحات موضوعية: *LUNG cancer treatment, *IPILIMUMAB, *PACLITAXEL, *CARBOPLATIN, *CLINICAL trials, *MONOCLONAL antibodies, *DRUG side effects

    النص الكامل

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    475OOverall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI).

    المؤلفون: Wu, Y-L1 (AUTHOR), Mok, T S K2 (AUTHOR), Han, J-Y3 (AUTHOR), Ahn, M-J4 (AUTHOR), Delmonte, A5 (AUTHOR), Ramalingam, S S6 (AUTHOR), Kim, S-W7 (AUTHOR), Shepherd, F A8 (AUTHOR), Laskin, J9 (AUTHOR), He, Y10 (AUTHOR), Akamatsu, H11 (AUTHOR), Theelen, W S M E12 (AUTHOR), Su, W-C13 (AUTHOR), John, T14 (AUTHOR), Sebastian, M15 (AUTHOR), Mann, H16 (AUTHOR), Miranda, M16 (AUTHOR), Laus, G17 (AUTHOR), Rukazenkov, Y17 (AUTHOR), Papadimitrakopoulou, V18 (AUTHOR)

    المصدر: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.

    مصطلحات موضوعية: *NON-small-cell lung carcinoma, *KINASE inhibitors, *PART-time employment, *STOCK options, *BODY surface area

    الشركة/الكيان: ASTRAZENECA PLC AZN, BRISTOL-Myers Squibb Co. 001288497 BMY

    النص الكامل

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث